Skip to main content
Clinical Trials/NL-OMON33397
NL-OMON33397
Recruiting
N/A

The assessment of microvascular alterations in renal transplant recipients with and without rejection - OPS-1

eids Universitair Medisch Centrum0 sites105 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
chronische allograft nefropathie
Sponsor
eids Universitair Medisch Centrum
Enrollment
105
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria for renal transplant patients:
  • 1\. Age: 18 \-70 years
  • 2\. Female or male
  • 3\. Kidney transplantation( living and cadaveric)
  • 4\. Patients who will undergo renal biopsy because of renal function impairment
  • 5\. Patients must be able to adhere to the study visit schedule and protocol requirements.
  • 6\. Patients must be able to give informed consent and the consent must be obtained prior to any study procedure.;Inclusion criteria for healthy controls:
  • 1\. Age: 18\-70
  • 2\. Female or male

Exclusion Criteria

  • Exclusion criteria for renal transplant patients:
  • 1\. Double organ transplantation
  • 2\. Patients with evidence of active infection or abcesses.
  • 3\. Patients suffering from hepatic failure.
  • 4\. Patients suffering from an active autoimmune disease
  • 5\. Malignancy (including lymphoproliferative disease) within the past 2\-5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence)
  • 6\. Patients who currently have an active opportunistic infection (e.g., herpes zoster \[shingles], cytomegalovirus (CMV), Pneumocystis carinii (PCP), aspergillosis, histoplasmosis, or mycobacteria other than TB)
  • 7\. Patients with epilepsy;Exclusion criteria for healthy controls:
  • 1\. Smoking (within 1 year prior to screening)
  • 2\. History of cardiovascular disease

Outcomes

Primary Outcomes

Not specified

Similar Trials